421 related articles for article (PubMed ID: 16985239)
21. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
22. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
23. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
Jonat W
MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
[No Abstract] [Full Text] [Related]
24. Tamoxifen in breast cancer: not so easy to write off.
Munshi A; Singh P
Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
[TBL] [Abstract][Full Text] [Related]
25. Progression of endocrine therapies for breast cancer: where are we headed?
Arnedos M; Smith I
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1651-64. PubMed ID: 18020931
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
27. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
[No Abstract] [Full Text] [Related]
28. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
29. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
30. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
Howell A; Dowsett M
Breast Cancer Res; 2004; 6(6):269-74. PubMed ID: 15535858
[TBL] [Abstract][Full Text] [Related]
31. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
Hu JC; Mokbel K
Eur J Surg Oncol; 2001 Jun; 27(4):335-7. PubMed ID: 11417974
[No Abstract] [Full Text] [Related]
32. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Gurwitz D; Newman W
J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
[No Abstract] [Full Text] [Related]
33. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
Ryan PD; Goss PE
Nat Clin Pract Oncol; 2005 Dec; 2(12):596-7. PubMed ID: 16341095
[No Abstract] [Full Text] [Related]
34. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
35. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
36. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
37. [Utility of neoadjuvant endocrine therapy for breast neoplasms].
Akashi-Tanaka S
Nihon Rinsho; 2007 Jun; 65 Suppl 6():559-62. PubMed ID: 17682211
[No Abstract] [Full Text] [Related]
38. [Breast neoplasms: predictive factors for endocrine therapy ].
Hayashi S
Nihon Rinsho; 2007 Jun; 65 Suppl 6():148-53. PubMed ID: 17682151
[No Abstract] [Full Text] [Related]
39. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
40. Aromatase in the context of breast and endometrial cancer. A review.
Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
